Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Clearbridge Investments LLC

Clearbridge Investments LLC trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,851,189 shares of the medical research company's stock after selling 242,394 shares during the period. Thermo Fisher Scientific accounts for 0.8% of Clearbridge Investments LLC's holdings, making the stock its 19th biggest position. Clearbridge Investments LLC owned about 0.48% of Thermo Fisher Scientific worth $963,044,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Geode Capital Management LLC lifted its holdings in Thermo Fisher Scientific by 1.7% in the 3rd quarter. Geode Capital Management LLC now owns 7,659,943 shares of the medical research company's stock valued at $4,719,477,000 after purchasing an additional 127,564 shares in the last quarter. Coldstream Capital Management Inc. lifted its stake in shares of Thermo Fisher Scientific by 11.4% in the third quarter. Coldstream Capital Management Inc. now owns 9,705 shares of the medical research company's stock worth $5,972,000 after buying an additional 995 shares in the last quarter. Greenwood Gearhart Inc. grew its stake in Thermo Fisher Scientific by 9.8% during the 3rd quarter. Greenwood Gearhart Inc. now owns 20,579 shares of the medical research company's stock valued at $12,730,000 after acquiring an additional 1,837 shares in the last quarter. Nordea Investment Management AB raised its holdings in Thermo Fisher Scientific by 23.6% in the 4th quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock valued at $28,868,000 after acquiring an additional 10,606 shares during the last quarter. Finally, S.E.E.D. Planning Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 6.2% during the 4th quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock worth $5,528,000 after purchasing an additional 618 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Remove Ads

Thermo Fisher Scientific Stock Down 3.0 %

NYSE:TMO traded down $15.09 during midday trading on Tuesday, reaching $482.51. The company had a trading volume of 1,837,520 shares, compared to its average volume of 1,623,572. Thermo Fisher Scientific Inc. has a 12-month low of $481.47 and a 12-month high of $627.88. The firm has a market capitalization of $182.03 billion, a price-to-earnings ratio of 29.19, a PEG ratio of 2.99 and a beta of 0.79. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The stock's fifty day simple moving average is $540.37 and its 200-day simple moving average is $551.02.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.36%. The ex-dividend date of this dividend is Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio is 10.41%.

Analysts Set New Price Targets

TMO has been the topic of a number of analyst reports. Bank of America reduced their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. UBS Group boosted their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Wells Fargo & Company lifted their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. Morgan Stanley increased their price target on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Finally, Citigroup decreased their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $653.23.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen Williamson sold 9,825 shares of the firm's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the transaction, the chief financial officer now directly owns 27,296 shares in the company, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,900 shares of company stock worth $13,106,062 over the last ninety days. Corporate insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.